GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advaxis Inc (OTCPK:ADXS) » Definitions » Piotroski F-Score

Advaxis (Advaxis) Piotroski F-Score

: 0 (As of Today)
View and export this data going back to 2005. Start your Free Trial

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Advaxis has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Advaxis's Piotroski F-Score or its related term are showing as below:


Advaxis Piotroski F-Score Historical Data

The historical data trend for Advaxis's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advaxis Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22
Piotroski F-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 4.00 2.00 4.00 4.00

Advaxis Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Mar23
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 4.00 4.00 1.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar23) TTM:Last Year (Jan22) TTM:
Net Income was -2.44 + -6.963 + -4.591 + -7.361 = $-21.36 Mil.
Cash Flow from Operations was -4.318 + -3.851 + -2.977 + -6.741 = $-17.89 Mil.
Revenue was 0.25 + 0 + 0 + 0.004 = $0.25 Mil.
Gross Profit was 0.25 + 0 + 0 + 0 = $0.25 Mil.
Average Total Assets from the begining of this year (Jan22)
to the end of this year (Mar23) was
(46.498 + 37.518 + 30.101 + 25.93 + 20.995) / 5 = $32.2084 Mil.
Total Assets at the begining of this year (Jan22) was $46.50 Mil.
Long-Term Debt & Capital Lease Obligation was $1.41 Mil.
Total Current Assets was $18.26 Mil.
Total Current Liabilities was $9.83 Mil.
Net Income was -5.107 + -3.334 + -5.444 + -0.365 = $-14.25 Mil.

Revenue was 1.375 + 0.25 + 0 + 0 = $1.63 Mil.
Gross Profit was 1.375 + 0.25 + 0 + 0 = $1.63 Mil.
Average Total Assets from the begining of last year (Jan21)
to the end of last year (Jan22) was
(45.947 + 55.771 + 51.022 + 46.78 + 46.498) / 5 = $49.2036 Mil.
Total Assets at the begining of last year (Jan21) was $45.95 Mil.
Long-Term Debt & Capital Lease Obligation was $0.01 Mil.
Total Current Assets was $43.12 Mil.
Total Current Liabilities was $3.72 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Advaxis's current Net Income (TTM) was -21.36. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Advaxis's current Cash Flow from Operations (TTM) was -17.89. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jan22)
=-21.355/46.498
=-0.45926707

ROA (Last Year)=Net Income/Total Assets (Jan21)
=-14.25/45.947
=-0.31013994

Advaxis's return on assets of this year was -0.45926707. Advaxis's return on assets of last year was -0.31013994. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Advaxis's current Net Income (TTM) was -21.36. Advaxis's current Cash Flow from Operations (TTM) was -17.89. ==> -17.89 > -21.36 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jan22 to Mar23
=1.41/32.2084
=0.0437774

Gearing (Last Year: Jan22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jan21 to Jan22
=0.005/49.2036
=0.00010162

Advaxis's gearing of this year was 0.0437774. Advaxis's gearing of last year was 0.00010162. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar23)=Total Current Assets/Total Current Liabilities
=18.261/9.833
=1.8571138

Current Ratio (Last Year: Jan22)=Total Current Assets/Total Current Liabilities
=43.116/3.719
=11.5934391

Advaxis's current ratio of this year was 1.8571138. Advaxis's current ratio of last year was 11.5934391. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Advaxis's number of shares in issue this year was 4.405. Advaxis's number of shares in issue last year was 1.82. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.25/0.254
=0.98425197

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1.625/1.625
=1

Advaxis's gross margin of this year was 0.98425197. Advaxis's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jan22)
=0.254/46.498
=0.0054626

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jan21)
=1.625/45.947
=0.03536684

Advaxis's asset turnover of this year was 0.0054626. Advaxis's asset turnover of last year was 0.03536684. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+0+0
=1

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Advaxis has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

Advaxis  (OTCPK:ADXS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Advaxis Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Advaxis's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Advaxis (Advaxis) Business Description

Traded in Other Exchanges
N/A
Address
9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ, USA, 8540
Advaxis Inc is a clinical-stage biotechnology company operating in the United States. It focuses on the discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate-Specific Antigen (PSA) associated with prostate cancer.
Executives
Roy Golan officer: Chief Financial Officer 24 GOLDA MEIR ST., HOLON L3 5840425
Yuval Cabilly director C/O BIOSIGHT THERAPEUTICS, 4 HASADOT STREET, RAMAT HASHARON L3 4704348
Pini Orbach director C/O BIOSIGHT THERAPEUTICS, 3 HAYARDEN STREET, AIRPORT CITY L3 7019802
Bridget A Martell director C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Israel Biotech Fund Ii, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Israel Biotech Fund Gp Partners Ii, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Murray A Goldberg director 2030 MAIN STREET, SUITE 1500, IRVINE CA 92614
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Vered Bisker-leib director C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Israel Biotech Fund I, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Amoon Growth Fund Limited Partnership 10 percent owner 34 YERUSHALAYIM RD., RAANANA L3 4350110
Israel Biotech Fund Gp Partners, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Yair Chaim Schindel 10 percent owner YERUSHALAYIM ROAD 34, BEIT GAMLA ENTRANCE B, RA'ANANA L3 4350110
I.b.f. Management Ltd. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Igor Gitelman officer: Chief Accounting Officer 201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070

Advaxis (Advaxis) Headlines

From GuruFocus

Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement

By Value_Insider Value_Insider 10-19-2022

Advaxis and Ayala Pharmaceuticals Complete Merger

By Stock market mentor Stock market mentor 01-19-2023